Clinical InvestigationCongestive Heart FailureVitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease
Section snippets
Study population
The PRIMO study enrolled 227 patients from 60 centers in 11 countries between July 2008 and September 2010. Details of the protocol and primary results have been reported previously.26 In brief, patients were 18 to 75 years old with LV hypertrophy on 2-dimensional transthoracic echocardiography (septal wall thickness of 1.1-1.7 cm in females, 1.2-1.8 cm in males),27 LV ejection fraction (LVEF) >50%, and estimated glomerular filtration rate (eGFR) of 15 to 60 mL/minute per 1.73m2. Patients on
Baseline characteristics
A total of 196 (86%) of the 227 enrolled patients in the PRIMO study had available longitudinal echocardiographic data; 103 were randomly assigned to paricalcitol; and 93, to placebo. Baseline characteristics were similar between groups (Table I). Participants were mostly white males with hypertension. Other cardiovascular risk factors, such as obesity and diabetes mellitus, were highly prevalent in both groups. Most participants were receiving RAAS inhibitors (79% in paricalcitol vs 80% in
Discussion
The nephrology community has long sought interventions to modify cardiac structure and function given the marked elevation in risk for cardiovascular disease and the almost universal findings of altered cardiac structure and function in this population. In this post hoc analysis of the PRIMO trial, we demonstrate that paricalcitol therapy over 48 weeks was associated with a significant decrease in LAVi in patients with CKD, despite similar blood pressure control and superimposed RAAS inhibitor
Disclosures
Dr. Thadhani received a coordinating grant from Abbot Laboratories to the Massachusetts General Hospital, speaker's fees and travel support from Abbot Laboratories. Drs. Pritchett, Andress, and Zhang are employees of Abbott Laboratories and may own Abbott stock or options. Drs. Agarwal, Zoccali, Wanner and Zehnder received honoraria from Abbott Laboratories for lectures or for participation in steering committee. Dr. Manning received travel support for a CMR meeting from Abbott Laboratories.
References (38)
- et al.
Left atrial enlargement: an early sign of hypertensive heart disease
Am Heart J
(1988) - et al.
Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension
J Am Coll Cardiol
(1991) - et al.
Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study)
Am J Cardiol
(2008) - et al.
Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction
J Am Coll Cardiol
(1993) - et al.
Pulmonary venous flow velocity: relation to hemodynamics, mitral flow velocity and left atrial volume, and ejection fraction
J Am Soc Echocardiogr
(1991) - et al.
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden
Am J Cardiol
(2002) - et al.
Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function
J Am Soc Echocardiogr
(1995) - et al.
Prognostic implications of left atrial volume index in patients in sinus rhythm
Am J Cardiol
(2010) - et al.
Increased left atrial volume index predicts a poor prognosis in patients with heart failure
J Card Fail
(2011) - et al.
Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction
J Am Coll Cardiol
(2000)
Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation
Am J Kidney Dis
Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD
Am J Kidney Dis
Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3
J Biol Chem
Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004)
Am J Cardiol
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
J Am Soc Echocardiogr
Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice
J Steroid Biochem Mol Biol
Vitamin D activates type A natriuretic peptide receptor gene transcription in inner medullary collecting duct cells
Kidney Int
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both
Am Heart J
Left atrial volume in end-stage renal disease: a prospective cohort study
J Hypertens
Cited by (101)
Vitamin D and the renin-angiotensin system
2023, Feldman and Pike's Vitamin D: Volume One: Biochemistry, Physiology and DiagnosticsUpdate on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease
2018, Seminars in NephrologyWorking Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4
2018, Advances in Chronic Kidney DiseaseUtilization of alfacalcidol and active vitamin D analogs in chronic kidney disease
2018, Nephrologie et TherapeutiqueVitamin D and Calcimimetics in Cardiovascular Disease
2018, Seminars in NephrologySubclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation
2018, AtherosclerosisCitation Excerpt :Chronic inflammation leads to oxidative stress, myocyte dysfunction and increased fibroblast activity causing myocardial collagen deposition and interstitial fibrosis [47–49], hence hampering myocardial contraction [50]. Furthermore, vitamin D deficiency has been related to cardiac tissue remodeling [51] and LV hypertrophy [52]. Since inflammatory pathways and oxidative stress seems to underlie the myocardial dysfunction, and taken into account the effects of vitamin D on tissue remodeling [52] and on anti-inflammatory and anti-oxidative pathways [53,54], the potential beneficial effects of vitamin D on myocardial dysfunction warrants future studies.